Introduction:

Coxitor 90 mg, manufactured by Beacon Pharmaceuticals Ltd and supplied by Orio Pharma, is a non-steroidal anti-inflammatory drug (NSAID) specifically designed to provide relief from the symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute pain. Containing Etoricoxib, Coxitor 90 mg selectively inhibits COX-2 (cyclooxygenase-2), an enzyme responsible for inflammation and pain. This targeted action makes Coxitor 90 mg an effective option for managing chronic conditions associated with inflammation and for providing relief from acute pain.

Manufacturing Excellence of Beacon Pharmaceuticals Ltd.:

Beacon Pharmaceuticals Ltd. is committed to producing high-quality pharmaceutical products that meet stringent international standards. The development of Coxitor 90 mg reflects Beacon’s dedication to advancing treatments for chronic inflammatory conditions through innovative research, rigorous quality control, and adherence to best manufacturing practices. Their focus on safety and efficacy ensures that Coxitor 90 mg is a reliable and effective option for patients seeking relief from arthritis and pain.

Mechanism of Action:

Coxitor 90 mg contains Etoricoxib, a selective COX-2 inhibitor. Unlike traditional NSAIDs that inhibit both COX-1 and COX-2 enzymes, Etoricoxib specifically targets COX-2, the enzyme responsible for the production of prostaglandins that cause pain and inflammation. By selectively inhibiting COX-2, Coxitor 90 mg effectively reduces inflammation and pain while minimizing the gastrointestinal side effects commonly associated with non-selective NSAIDs. This selective action makes Coxitor 90 mg particularly suitable for long-term use in managing chronic inflammatory conditions.

Clinical Applications:

Coxitor 90 mg is indicated for the treatment of:

• Osteoarthritis: Coxitor 90 mg is used to relieve the pain and inflammation associated with osteoarthritis, improving joint function and quality of life for patients with this degenerative joint disease.
• Rheumatoid Arthritis: Coxitor 90 mg provides effective relief from the pain, swelling, and stiffness associated with rheumatoid arthritis, a chronic autoimmune disorder that affects the joints.
• Ankylosing Spondylitis: Coxitor 90 mg is also indicated for the treatment of ankylosing spondylitis, a type of arthritis that primarily affects the spine, reducing inflammation and improving mobility.
• Acute Pain: Coxitor 90 mg is effective in managing acute pain, including pain associated with dental procedures and minor surgeries.

Clinical studies have demonstrated that Etoricoxib is highly effective in reducing pain and inflammation in patients with chronic arthritis and in providing rapid relief from acute pain.

Dosage and Administration:

The recommended dosage of Coxitor 90 mg varies depending on the specific condition being treated. For osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, the typical dosage is one 90 mg tablet once daily. For the management of acute pain, the dosage may vary, but it is generally prescribed as a short-term treatment. The tablets should be swallowed whole with water, with or without food. It is important for patients to follow their healthcare provider’s instructions carefully and not exceed the recommended dosage. Regular monitoring of renal function, liver function, and overall health is essential, especially in long-term use, to assess the response to therapy and manage any potential side effects.

Benefits of Coxitor 90 mg:

• Targeted Pain Relief: Coxitor 90 mg provides effective and targeted relief from pain and inflammation associated with arthritis and acute conditions.
• Reduced Gastrointestinal Side Effects: By selectively inhibiting COX-2, Coxitor 90 mg minimizes the risk of gastrointestinal complications commonly associated with non-selective NSAIDs.
• Improved Quality of Life: Coxitor 90 mg helps reduce pain, improve joint function, and enhance the overall quality of life for patients with chronic inflammatory conditions.
• Convenient Once-Daily Dosing: The once-daily dosing of Coxitor 90 mg offers convenience and ensures consistent management of chronic pain and inflammation.

Supplier: Orio Pharma

Orio Pharma ensures that Coxitor 90 mg is readily available to healthcare providers and patients, offering reliable access to this essential treatment for arthritis and pain. Their commitment to efficient supply and distribution supports effective management of chronic inflammatory conditions, helping to improve patient outcomes.

Conclusion:

Coxitor 90 mg (Etoricoxib) by Beacon Pharmaceuticals Ltd, supplied by Orio Pharma, represents a significant advancement in the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute pain. This targeted therapy offers effective relief from pain and inflammation while minimizing the gastrointestinal side effects associated with traditional NSAIDs. By incorporating Coxitor 90 mg into their treatment plans, healthcare providers can offer patients a reliable and effective strategy for managing chronic inflammatory conditions, ultimately leading to better health outcomes and an improved quality of life.